Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Treatment of wild-type human immunodeficiency virus [HIV-1(IIIB)]-infected cell cultures with the thiocarboxanilide UC-781 under low selective pressure (i.e., 0.01 microg/ml) resulted in the emergence of V106A RT mutant virus. On increasing drug concentrations (stepwise up to 30 microg/ml) the virus retained the V106A RT mutation but acquired the novel F227L mutation in the RT genome in addition to the L100I, K1O1I, and Y181C mutations. This multiple-mutant virus proved highly resistant to virtually all nonnucleoside RT inhibitors (NNRTIs) (e.g., nevirapine, delavirdine, and loviride), but retained full sensitivity to nucleoside analogs such as AZT, ddI, (-)FTC, and 3TC. The F227 amino acid is highly conserved in HIV-1 strains and forms part of the NNRTI-binding pocket. Our model suggests a hydrophobic interaction between F227 and the chloro atom of UC-781.

Original publication

DOI

10.1089/aid.1998.14.255

Type

Journal article

Journal

AIDS research and human retroviruses

Publication Date

02/1998

Volume

14

Pages

255 - 260

Addresses

Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium. Jan.Balzarini@rega.kuleuven.ac.be

Keywords

Tumor Cells, Cultured, Humans, HIV-1, Anilides, Furans, Reverse Transcriptase Inhibitors, Anti-HIV Agents, Microbial Sensitivity Tests, Evolution, Molecular, Drug Resistance, Microbial, Dose-Response Relationship, Drug, Mutation, Genes, Viral, HIV Reverse Transcriptase